Literature DB >> 15965300

A quantitative analysis of cedar pollen-specific immunoglobulins in nasal lavage supported the local production of specific IgE, not of specific IgG.

Tomoaki Yoshida1, Ayako Usui, Taeko Kusumi, Shigeru Inafuku, Tsuyoshi Sugiyama, Naoki Koide, Takashi Yokochi.   

Abstract

Many studies have proved the relevance of local immune responses, rather than systemic immunity, to the pathogenesis of allergic rhinitis. Indeed, allergen-specific B lymphocyte undergoes class switching to IgE in situ. However, the relative contribution of in situ production to the amount in serum is still ambiguous. Here, a quantitative comparison of the local concentration of allergen-specific IgE with the systemic concentration was explored for the estimation. Among seasonal rhinitis patients, total and Japanese cedar pollen (JCP)-specific IgE, IgA and IgG antibodies were quantified in nasal lavage fluid (NLF) and serum with the time-resolved fluorescence immunosorbent assay. Although the total amounts of IgE and IgG classes in the NLF, which were apparently passive discharge from the mucosal tissue, were smaller and variable, the relative proportions of JCP-specific antibodies could be quantitatively compared between NLF and serum or between subjects. The proportions of specific IgE in the NLF were remarkably higher than in serum (average 13.2-fold) in most subjects, which strongly supported the predominant in situ production of the specific IgE and subsequent dilutions in the systemic circulations. Similar but smaller values were obtained for IgA (average 3.7-fold). In contrast, the specific proportions of IgG in the NLF were surprisingly consistent with serum (average 1.0-fold), suggesting that the specific IgG was mostly produced in the downstream lymphoid organs. The local productions of specific IgE would encourage the topical therapies and the usage of the NLF for the diagnosis of allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965300     DOI: 10.1111/j.1348-0421.2005.tb03758.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  7 in total

Review 1.  Epithelium: at the interface of innate and adaptive immune responses.

Authors:  Robert P Schleimer; Atsushi Kato; Robert Kern; Douglas Kuperman; Pedro C Avila
Journal:  J Allergy Clin Immunol       Date:  2007-10-18       Impact factor: 10.793

Review 2.  B-lymphocyte lineage cells and the respiratory system.

Authors:  Atsushi Kato; Kathryn E Hulse; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

Review 3.  Asthma outcomes: biomarkers.

Authors:  Stanley J Szefler; Sally Wenzel; Robert Brown; Serpil C Erzurum; John V Fahy; Robert G Hamilton; John F Hunt; Hirohito Kita; Andrew H Liu; Reynold A Panettieri; Robert P Schleimer; Michael Minnicozzi
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

Review 4.  IgE Test in Secretions of Patients with Respiratory Allergy.

Authors:  Carmen Rondón; Ibon Eguíluz-Gracia; Mohamed H Shamji; Janice A Layhadi; María Salas; María José Torres; Paloma Campo
Journal:  Curr Allergy Asthma Rep       Date:  2018-10-13       Impact factor: 4.806

5.  Molecular patterns in the isotype-specific antibody responses to the major cedar aeroallergen Jun a 1.

Authors:  Randall M Goldblum; Rumali S Madagoda-Desilva; Yueqing Zhang; Julius van Bavel; Terumi Midoro-Horiuti
Journal:  Mol Immunol       Date:  2018-08-29       Impact factor: 4.407

6.  Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.

Authors:  Prabhas Jagdale; Armin Sepp; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-10-20       Impact factor: 2.410

Review 7.  Local immunoglobulin e in the nasal mucosa: clinical implications.

Authors:  Els De Schryver; Lien Devuyst; Lara Derycke; Melissa Dullaers; Thibaut Van Zele; Claus Bachert; Philippe Gevaert
Journal:  Allergy Asthma Immunol Res       Date:  2015-03-05       Impact factor: 5.764

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.